Analyst Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report) and keeping the price target at $46.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Serge Belanger’s rating is based on a combination of factors discussed during the fireside chat with Collegium Pharmaceutical’s leadership at the Needham Healthcare Conference. One of the key elements influencing the Buy rating is the minimal impact expected from tariffs, which suggests stability in the company’s operational costs.
Additionally, the discussion highlighted the growth potential for 2025, driven by products like Jornay PM and the company’s business development aspirations. Although there is a minor adjustment in the sales model due to expected seasonal slowdowns, the overall outlook remains positive, supporting the Buy recommendation.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COLL in relation to earlier this year.